FDA Expands Approval of Sutent to Reduce the Risk of Kidney Cancer Returning
On November 16, 2017, The U.S. Food and Drug Administration approved Sutent for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) reoccurrence after a kidney has been removed (nephrectomy). The following statement can be attributed to Neal M. Shore, MD, FACS, president of LUGPA:
“The FDA’s approval of the first adjuvant treatment for patients with renal cell carcinoma returning after a nephrectomy is a lifesaving advancement and important news for many of us who treat patients with kidney cancer. With no other FDA-approved agent targeting recurrence, this groundbreaking treatment will have widespread implications for thousands of patients per year.
As leaders in advancing quality care for patients, I anticipate that LUGPA’s member practices will begin implementing this treatment immediately into the care paradigm of patients for whom it is most appropriate. This will serve as one of the many tools we use in conjunction with others, such as immunotherapy and targeted molecular therapies, to achieve the best possible outcomes for patients. We applaud the FDA’s bold decision to approve this treatment, which will solve a major unmet need in healthcare.”
About LUGPA LUGPA is an Association that represents independent urology group practices in the U.S., with more than 2,300 physicians who make up more than 25 percent of the nation’s practicing urologists, and provide more than 30 percent of the total urologic care in the U.S. The Association is committed to providing the best resources and information for its member practices through advocacy, research, data collection and benchmarking efforts. LUGPA advocates for independent urology practices by promoting quality clinical outcomes, fostering new opportunities and improving advocacy in the legislative and regulatory arenas. For more information, visit lugpa.org.